Pulmonology

GOLD 2026 Global Strategy for Prevention, Diagnosis and Management of COPD

Global Initiative for Chronic Obstructive Lung Disease

Sixth major revision of the GOLD strategy document; emphasizes earlier and better COPD detection, completely revises the exacerbations and multimorbidity chapters, and adds a new chapter on AI and emerging technologies in COPD.

What changed in this edition

  • Emphasis on earlier and better diagnosis of COPD, including in younger and at-risk populations.
  • Chapter 4 on exacerbations completely revised; Chapter 5 on multimorbidity completely revised.
  • New chapter on artificial intelligence and emerging technologies in COPD.
  • Dupilumab endorsed as add-on therapy for patients with type 2 inflammation (blood eos ≥300) and continued exacerbations.
  • Single-inhaler LABA/LAMA/ICS triple therapy endorsed for group E with eos ≥100 or frequent exacerbations.
  • Alpha-1 antitrypsin testing recommended once in every COPD diagnosis.
  • Structured pulmonary rehab early after hospitalization for exacerbation.
  • Smoking cessation pharmacotherapy and vaccination integrated into every visit.

Clinical takeaways

Diagnose correctly

Post-bronchodilator FEV1/FVC <0.7 in a symptomatic patient with exposure. Differentiate from asthma-COPD overlap using reversibility, atopy, and eosinophils. Order AAT level once.

ABE-based initial therapy

Group A: short-acting bronchodilator or LAMA/LABA. Group B: LABA+LAMA. Group E: LABA+LAMA; add ICS if eos ≥300 or frequent exacerbations. Single-inhaler triple preferred.

Biologics

Dupilumab 300 mg every 2 weeks for patients with ≥2 moderate or ≥1 severe exacerbation in prior year, eos ≥300, on triple therapy. Expect ~30% exacerbation reduction.

Exacerbation bundle

Systemic corticosteroids (prednisone 40 mg x 5 days), antibiotics if increased sputum purulence, short-acting bronchodilators, NIV for hypercapnic respiratory failure, early pulmonary rehab referral.

Cessation and vaccination

Offer varenicline or combination NRT plus counseling at every visit. Ensure pneumococcal, influenza, COVID-19, RSV, and pertussis vaccination up to date.

Supporting trials

  • BOREASPubMed 37272521

    Dupilumab reduced exacerbations by 30% in eosinophilic COPD.

  • NOTUSPubMed 38767614

    Confirmed BOREAS findings; supported regulatory approval.

  • ETHOSPubMed 32579807

    Budesonide/glycopyrrolate/formoterol reduced exacerbations and mortality vs dual therapy.

  • IMPACTPubMed 29668352

    FF/UMEC/VI triple therapy reduced exacerbations and mortality signal vs dual therapy.

Related reading

Clinical Reasoning

GOLD 2026 COPD Guidelines: Triple Therapy, Biologics, and Exacerbation Prevention

The 2026 GOLD report updates the COPD management framework with revised ABCD grouping, expanded triple therapy recommendations, and emerging biologic therapies for eosinophilic COPD. A practical guide for pulmonologists and primary care.

← Back to all guidelines